Dapagliflozin to prevent irregular heart rhythm after bypass surgery
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give written consent.
- You are scheduled for planned (elective) CABG surgery, with a heart-lung machine, possibly with valve/aortic procedures.
- You have NOT taken an SGLT2 inhibitor (like dapagliflozin) in the last 8 weeks.
- You have not had atrial fibrillation in the past.
- You have a stable blood pressure (no symptoms of low blood pressure, and systolic BP is not <95 mmHg on at least two of three checks) at enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This study tests whether a medicine called dapagliflozin can reduce abnormal electrical activity in the heart by targeting fat around the heart in people with atrial fibrillation who are scheduled for a first catheter ablation. It may help improve the success of the procedure.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This trial tests if dapagliflozin, a medication for diabetes and heart failure, can help prevent atrial fibrillation from returning after your first catheter ablation procedure for AF.
Hear when a new Chronic Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.